Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions. Journal of the National Cancer Institute Lam, W. K., King, A. D., Miller, J. A., Liu, Z., Yu, K. J., Chua, M. L., Ma, B. B., Chen, M. Y., Pinsky, B. A., Lou, P. J., Woo, J. K., Hsu, W. L., Simon, J., Doolan, D. L., Waterboer, T., Hui, E. P., Li, H., Tsang, R. K., Wong, K. C., Goh, J. P., Vlantis, A. C., Ai, Q. Y., Wong, L. M., Abdullah, V., Lin, J. C., Chen, C. J., Pfeiffer, R. M., Le, Q. T., Lee, A. W., Ji, M., Cao, S., Ma, J., Chan, A. T., Chan, K. C., Hildesheim, A. 2023


A meeting of experts was held in November 2021 to review and discuss available data on performance of Epstein-Barr virus (EBV)-based approaches to screen for early-stage nasopharyngeal carcinoma (NPC) and methods for the investigation and management of screen-positive individuals. Serum EBV antibody and plasma EBV DNA testing methods were considered. Both approaches were found to have favorable performance characteristics and to be cost-effective in high-risk populations. In addition to endoscopy, use of magnetic resonance imaging (MRI) to investigate screen-positive individuals was found to increase the sensitivity of NPC detection with minimal impact on cost-effectiveness of the screening program.

View details for DOI 10.1093/jnci/djad012

View details for PubMedID 36723440